Table 2.
Studies using octreotide to assess food intake and satiety after bariatric surgery.
| Author | Groups | No (% F) |
Octreotide Dose/Saline | Meal | Age (years) |
BMI Preop (kg/m2) |
BMI at Assessment (kg/m2) | Time of Assessment (postoperative) |
Food Intake with Octreotide vs. Placebo | Satiety/Fullness with Octreotide vs. Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Le Roux 2007 [19] | RYGB AGB |
7 (NR) 6 (NR) |
100 mcg octreotide/ 1 mL saline |
Ad libitum meal 60 min after octreotide/saline | 43 ± 4.5 41.1 ± 5.6 |
44.5 ± 2.9 41.9 ± 7.5 |
33.2 ± 1.9 29.6 ± 1.5 |
9.5 ± 1.5 months 17.0 ± 1.4 months |
↑NC RYGB ↔ AGB |
↑NC RYGB (Fullness) ↔ AGB (Fullness) |
| De Hollanda 2015 [124] |
RYGB, secondary “poor” responders (EWL% <50%) |
19 (68.4%) | 100 mcg octreotide/ 1 mL saline |
Ad libitum meal 60 min after octrotide/saline | 43.9 ± 10.3 | 46.9 ± 5.0 | 39.9 ± 4.0 | 6.5 ± 1.1 years | +53.7% (↑ND) secondary “poor” responders | ↓(satiety) in secondary “poor” responders |
| RYGB, “good” responders (EWL >50%) |
23 (78.3%) | 42.1 ± 10 | 45.6 ± 5.6 | 28.7 ± 3.3 | 6.0 ± 2.1 years | +47.3% (↑) “good” responders | ↓ (satiety) in “good” responders | |||
| Bojsen-Moller 2020 [128] (abstract) |
RYGB, primary “poor” responders (EBLmax <50%) |
20 (100%) | 1 mcg/kg octreotide (max 100 mcg)/saline | Standardised MMTT 30 min after octreotide/saline and then ad libitum meal at 270 min | 51 ± 9 | 43.1 ± 4.0 | 40 ± 4.1 | 4.8 ± 2.0 years | −0.5% (↔) primary “poor” responders | NR |
| RYGB, “good” responders (EBLmax >60%) |
20 (100%) | 51 ± 9 | 43.0 ± 3.6 | 29.2 ± 3.3 | 4.8 ± 1.4 years | +23% (↑*) “good” responders | NR |
Roux-en-Y gastric bypass, EWL%: Excess Weight Loss, EBLmax: Maximum Excess BMI Loss, F: Female, MMTT: Mixed Meal Tolerance Test, NR: Not Reported, ↑: increased with octreotide vs. placebo, ↔: no change with octreotide vs. placebo, ↓: reduced with octreotide vs. placebo,*: significant difference between study groups on the outcome change with octreotide vs. placebo, NC: no comparison performed between study groups on the outcome change with octreotide vs. placebo, ND: no difference between study groups on the outcome change with octreotide vs. placebo.